Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Return on Invested Capital (2016 - 2025)

Ligand Pharmaceuticals' Return on Invested Capital history spans 15 years, with the latest figure at 0.03% for Q4 2025.

  • For Q4 2025, Return on Invested Capital fell 1.0% year-over-year to 0.03%; the TTM value through Dec 2025 reached 0.03%, down 1.0%, while the annual FY2025 figure was 0.03%, 1.0% down from the prior year.
  • Return on Invested Capital for Q4 2025 was 0.03% at Ligand Pharmaceuticals, up from 0.02% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.14% in Q2 2021 and bottomed at 0.06% in Q1 2025.
  • The 5-year median for Return on Invested Capital is 0.03% (2023), against an average of 0.04%.
  • The largest YoY upside for Return on Invested Capital was 14bps in 2021 against a maximum downside of -14bps in 2021.
  • A 5-year view of Return on Invested Capital shows it stood at 0.13% in 2021, then plummeted by -105bps to 0.01% in 2022, then skyrocketed by 326bps to 0.01% in 2023, then soared by 194bps to 0.04% in 2024, then decreased by -25bps to 0.03% in 2025.
  • Per Business Quant, the three most recent readings for LGND's Return on Invested Capital are 0.03% (Q4 2025), 0.02% (Q3 2025), and 0.04% (Q2 2025).